Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies

A report from the children's oncology group

Kristina K. Hardy, Leanne Embry, John A. Kairalla, Shanjun Helian, Meenakshi Devidas, Daniel Armstrong, Stephen Hunger, William L. Carroll, Eric Larsen, Elizabeth A. Raetz, Mignon L. Loh, Wenjian Yang, Mary V. Relling, Robert B. Noll, Naomi Winick

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits that are associated with treatment, individual, and environmental factors. This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL. Methods Participants were randomly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG asparaginase without leucovorin rescue. Patients were also randomly assigned to corticosteroid therapy that included either dexamethasone or prednisone. A neurocognitive evaluation of intellectual functioning (IQ), working memory, and processing speed (PS) was conducted 8 to 24 months after treatment completion (n = 192). Results The method of MTX delivery and corticosteroid assignment were unrelated to differences in neurocognitive outcomes after controlling for ethnicity, race, age, gender, insurance status, and time off treatment; however, survivors who were age <10 years at diagnosis (n = 89) had significantly lower estimated IQ (P < .001) and PS scores (P = .02) compared with participants age ≥ 10 years. In addition, participants who were covered by US public health insurance had estimated IQs that were significantly lower (P <.001) than those with US private or military insurance. Conclusion Children with high-risk B-lineage ALL who were age <10 years at diagnosis are at risk for deficits in IQ and PS in the absence of cranial radiation, regardless of MTX delivery or corticosteroid type. These data may serve as a basis for developing screening protocols to identify children who are at high risk for deficits so that early intervention can be initiated to mitigate the impact of therapy on neurocognitive outcomes.

Original languageEnglish (US)
Pages (from-to)2700-2707
Number of pages8
JournalJournal of Clinical Oncology
Volume35
Issue number23
DOIs
StatePublished - Aug 10 2017

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Adrenal Cortex Hormones
Leucovorin
Survivors
Therapeutics
Insurance Coverage
Health Insurance
Prednisone
Insurance
Short-Term Memory
Dexamethasone
Public Health
Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies : A report from the children's oncology group. / Hardy, Kristina K.; Embry, Leanne; Kairalla, John A.; Helian, Shanjun; Devidas, Meenakshi; Armstrong, Daniel; Hunger, Stephen; Carroll, William L.; Larsen, Eric; Raetz, Elizabeth A.; Loh, Mignon L.; Yang, Wenjian; Relling, Mary V.; Noll, Robert B.; Winick, Naomi.

In: Journal of Clinical Oncology, Vol. 35, No. 23, 10.08.2017, p. 2700-2707.

Research output: Contribution to journalArticle

Hardy, KK, Embry, L, Kairalla, JA, Helian, S, Devidas, M, Armstrong, D, Hunger, S, Carroll, WL, Larsen, E, Raetz, EA, Loh, ML, Yang, W, Relling, MV, Noll, RB & Winick, N 2017, 'Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies: A report from the children's oncology group', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2700-2707. https://doi.org/10.1200/JCO.2016.71.7587
Hardy, Kristina K. ; Embry, Leanne ; Kairalla, John A. ; Helian, Shanjun ; Devidas, Meenakshi ; Armstrong, Daniel ; Hunger, Stephen ; Carroll, William L. ; Larsen, Eric ; Raetz, Elizabeth A. ; Loh, Mignon L. ; Yang, Wenjian ; Relling, Mary V. ; Noll, Robert B. ; Winick, Naomi. / Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies : A report from the children's oncology group. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 23. pp. 2700-2707.
@article{d6e90927e93b4c8ab278734feeca25e4,
title = "Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies: A report from the children's oncology group",
abstract = "Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits that are associated with treatment, individual, and environmental factors. This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL. Methods Participants were randomly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG asparaginase without leucovorin rescue. Patients were also randomly assigned to corticosteroid therapy that included either dexamethasone or prednisone. A neurocognitive evaluation of intellectual functioning (IQ), working memory, and processing speed (PS) was conducted 8 to 24 months after treatment completion (n = 192). Results The method of MTX delivery and corticosteroid assignment were unrelated to differences in neurocognitive outcomes after controlling for ethnicity, race, age, gender, insurance status, and time off treatment; however, survivors who were age <10 years at diagnosis (n = 89) had significantly lower estimated IQ (P < .001) and PS scores (P = .02) compared with participants age ≥ 10 years. In addition, participants who were covered by US public health insurance had estimated IQs that were significantly lower (P <.001) than those with US private or military insurance. Conclusion Children with high-risk B-lineage ALL who were age <10 years at diagnosis are at risk for deficits in IQ and PS in the absence of cranial radiation, regardless of MTX delivery or corticosteroid type. These data may serve as a basis for developing screening protocols to identify children who are at high risk for deficits so that early intervention can be initiated to mitigate the impact of therapy on neurocognitive outcomes.",
author = "Hardy, {Kristina K.} and Leanne Embry and Kairalla, {John A.} and Shanjun Helian and Meenakshi Devidas and Daniel Armstrong and Stephen Hunger and Carroll, {William L.} and Eric Larsen and Raetz, {Elizabeth A.} and Loh, {Mignon L.} and Wenjian Yang and Relling, {Mary V.} and Noll, {Robert B.} and Naomi Winick",
year = "2017",
month = "8",
day = "10",
doi = "10.1200/JCO.2016.71.7587",
language = "English (US)",
volume = "35",
pages = "2700--2707",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies

T2 - A report from the children's oncology group

AU - Hardy, Kristina K.

AU - Embry, Leanne

AU - Kairalla, John A.

AU - Helian, Shanjun

AU - Devidas, Meenakshi

AU - Armstrong, Daniel

AU - Hunger, Stephen

AU - Carroll, William L.

AU - Larsen, Eric

AU - Raetz, Elizabeth A.

AU - Loh, Mignon L.

AU - Yang, Wenjian

AU - Relling, Mary V.

AU - Noll, Robert B.

AU - Winick, Naomi

PY - 2017/8/10

Y1 - 2017/8/10

N2 - Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits that are associated with treatment, individual, and environmental factors. This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL. Methods Participants were randomly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG asparaginase without leucovorin rescue. Patients were also randomly assigned to corticosteroid therapy that included either dexamethasone or prednisone. A neurocognitive evaluation of intellectual functioning (IQ), working memory, and processing speed (PS) was conducted 8 to 24 months after treatment completion (n = 192). Results The method of MTX delivery and corticosteroid assignment were unrelated to differences in neurocognitive outcomes after controlling for ethnicity, race, age, gender, insurance status, and time off treatment; however, survivors who were age <10 years at diagnosis (n = 89) had significantly lower estimated IQ (P < .001) and PS scores (P = .02) compared with participants age ≥ 10 years. In addition, participants who were covered by US public health insurance had estimated IQs that were significantly lower (P <.001) than those with US private or military insurance. Conclusion Children with high-risk B-lineage ALL who were age <10 years at diagnosis are at risk for deficits in IQ and PS in the absence of cranial radiation, regardless of MTX delivery or corticosteroid type. These data may serve as a basis for developing screening protocols to identify children who are at high risk for deficits so that early intervention can be initiated to mitigate the impact of therapy on neurocognitive outcomes.

AB - Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits that are associated with treatment, individual, and environmental factors. This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL. Methods Participants were randomly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG asparaginase without leucovorin rescue. Patients were also randomly assigned to corticosteroid therapy that included either dexamethasone or prednisone. A neurocognitive evaluation of intellectual functioning (IQ), working memory, and processing speed (PS) was conducted 8 to 24 months after treatment completion (n = 192). Results The method of MTX delivery and corticosteroid assignment were unrelated to differences in neurocognitive outcomes after controlling for ethnicity, race, age, gender, insurance status, and time off treatment; however, survivors who were age <10 years at diagnosis (n = 89) had significantly lower estimated IQ (P < .001) and PS scores (P = .02) compared with participants age ≥ 10 years. In addition, participants who were covered by US public health insurance had estimated IQs that were significantly lower (P <.001) than those with US private or military insurance. Conclusion Children with high-risk B-lineage ALL who were age <10 years at diagnosis are at risk for deficits in IQ and PS in the absence of cranial radiation, regardless of MTX delivery or corticosteroid type. These data may serve as a basis for developing screening protocols to identify children who are at high risk for deficits so that early intervention can be initiated to mitigate the impact of therapy on neurocognitive outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85028762924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028762924&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.71.7587

DO - 10.1200/JCO.2016.71.7587

M3 - Article

VL - 35

SP - 2700

EP - 2707

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -